Wednesday, March 09, 2011 1:00:33 PM
Saying he published articles about other drugs does not make him the inventor of Alimta. It's like asking if Menon ever made a table and hearing "well, he made 200 chairs".
Great, but that wasn't the question.
NVVC put out a press release sayung...
Dr. Menon is a well known Pharmaceutical Scientist and Executive. He was awarded the Employee of the Year, Presidents Award (1999) at Eli Lilly, where he was a co-inventor of two drugs GEMZAR and ALIMTA which account for nearly one billion dollars in annual sales. Prior to that, he was Senior Research Scientist at Bayer. At present, he is on the board of directors of KARD Scientific, MA, and Biological Supplies, NY, and scientific advisor to Nexus Pharmaceuticals.
http://www.aegis.com/NEWS/BW/2005/BW050609.html
We now know that this information is false. He certainly wasn't "co-inventor" of those drugs. His name appears nowhere on the patents. Those who actually invented the drugs say he had a minor role.
Menon admits himself that he lied...
When asked about these inconsistencies during a brief follow up phone interview with Menon, he stood his ground, at least at first. "I am one of the creators" of the Eli Lilly drugs, he said at the start of the phone call.But as the conversation progressed, he began to downplay his role to that of a member of a team that developed the drugs, and finally explained that his work was actually limited to animal testing.
http://www.zoominfo.com/search#search/profile/person?personId=1289170051&targetid=profile
Contrary to the claims of some here, the magazine never issued a retraction of the article.
NNVC also claimed Menon holds patents that nobody can find: http://www.nanoviricides.com/NNVC%20presentation.pdf
Why, if these claims are true, does NNVC no longer make them?
Why, since they know they he has lied about his research history, does NNVC employ him to do their research?
In the future, Feelgood, please put some evidence behind your claims.
Recent NNVC News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM